Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Preferred Stock Liabilities (2021 - 2022)

Historic Preferred Stock Liabilities for Coeptis Therapeutics Holdings (COEP) over the last 2 years, with Q3 2022 value amounting to $33.3 million.

  • Coeptis Therapeutics Holdings' Preferred Stock Liabilities fell 5608.55% to $33.3 million in Q3 2022 from the same period last year, while for Sep 2022 it was $33.3 million, marking a year-over-year decrease of 5608.55%. This contributed to the annual value of $75.8 million for FY2021, which is N/A changed from last year.
  • Coeptis Therapeutics Holdings' Preferred Stock Liabilities amounted to $33.3 million in Q3 2022, which was down 5608.55% from $33.0 million recorded in Q2 2022.
  • In the past 5 years, Coeptis Therapeutics Holdings' Preferred Stock Liabilities registered a high of $75.8 million during Q4 2021, and its lowest value of $33.0 million during Q2 2022.